-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The earnings season is approaching, and major MNCs (multinational pharmaceutical companies) have successively released their semi-annual reports
.
.
Pfizer, which has the first growth rate in 2021 (up 95% year-on-year), remains firmly in MNCTOP1 with the growth of new crown vaccines and new crown drugs, and ushered in a double-digit growth of 60% in the first half of the year
.
.
According to the total revenue of pharmaceutical companies, the top 10 global revenue are: Pfizer ($53.
402 billion), Johnson & Johnson ($47.
446 billion), Roche ($33.
761 billion), Merck ($30.
494 billion), AbbVie ($28.
121 billion) $), Novartis ($25.
312 billion), Bristol-Myers Squibb ($23.
535 billion), AstraZeneca ($21.
161 billion), Sanofi ($20.
122 billion), GlaxoSmithKline ($17.
194 billion)
.
402 billion), Johnson & Johnson ($47.
446 billion), Roche ($33.
761 billion), Merck ($30.
494 billion), AbbVie ($28.
121 billion) $), Novartis ($25.
312 billion), Bristol-Myers Squibb ($23.
535 billion), AstraZeneca ($21.
161 billion), Sanofi ($20.
122 billion), GlaxoSmithKline ($17.
194 billion)
.
According to the MNC semi-annual report, the top 10 best-selling drugs in 2022H1 are as follows:
Now, let's take a closer look at the performance of each company
.
.
Top 10 companies
Pfizer
According to Pfizer’s financial report, 2022H1 revenue is US$53.
402 billion, an increase of 60% from US$33.
415 billion in the first half of 2021
.
And its net profit growth has reached 70%
.
Among them, the vaccine Comirnaty is worth 22.
1 billion US dollars, and the new crown specific drug Paxlovid is 9.
6 billion US dollars, or about 31.
7 billion US dollars, which are the main income of the company
.
The revenue of its new crown products alone directly surpasses the 32 billion US dollars of Roche, a TOP10MNC
.
402 billion, an increase of 60% from US$33.
415 billion in the first half of 2021
.
And its net profit growth has reached 70%
.
Among them, the vaccine Comirnaty is worth 22.
1 billion US dollars, and the new crown specific drug Paxlovid is 9.
6 billion US dollars, or about 31.
7 billion US dollars, which are the main income of the company
.
The revenue of its new crown products alone directly surpasses the 32 billion US dollars of Roche, a TOP10MNC
.
Excluding its new crown field, Pfizer's other main lines of business, breast cancer drug Ibrance (Aiboxin) 25.
57 billion US dollars, prostate cancer drug Xtandi (Astery) 5.
58 billion US dollars in the tumor field have a certain amount of decline year-on-year
.
57 billion US dollars, prostate cancer drug Xtandi (Astery) 5.
58 billion US dollars in the tumor field have a certain amount of decline year-on-year
.
Relatively speaking, its Eliquis (apixaban) ($3.
537 billion, +13%), Prevnar family (Streptococcus pneumoniae vaccine) $2.
994 billion (+19% year-on-year), rare heart disease drug Vyndaqel/Vyndamax (Vivan Heart) $1.
164 billion (+22% year-on-year), Inlyta (axitinib) ($508 million, +4% year-on-year)
.
537 billion, +13%), Prevnar family (Streptococcus pneumoniae vaccine) $2.
994 billion (+19% year-on-year), rare heart disease drug Vyndaqel/Vyndamax (Vivan Heart) $1.
164 billion (+22% year-on-year), Inlyta (axitinib) ($508 million, +4% year-on-year)
.
Johnson & Johnson
Johnson & Johnson's 2022H1 financial report shows that its revenue has also reached $47.
446 billion, a year-on-year increase of 4.
0%
.
But the pharmaceutical business accounted for $26.
186 billion of that, up 6.
5% year-on-year
.
Analysis of its main top three products: STELARA (ustekinumab), one of the three giants in the field of self-immunity, was $4.
887 billion (+10.
5% year-on-year), and DARZALEX (daratumumab) was $3.
842 billion ( +37.
0% YoY) and its Imbruvica (ibrutinib) of $2.
008 billion (-10.
4% YoY)
.
446 billion, a year-on-year increase of 4.
0%
.
But the pharmaceutical business accounted for $26.
186 billion of that, up 6.
5% year-on-year
.
Analysis of its main top three products: STELARA (ustekinumab), one of the three giants in the field of self-immunity, was $4.
887 billion (+10.
5% year-on-year), and DARZALEX (daratumumab) was $3.
842 billion ( +37.
0% YoY) and its Imbruvica (ibrutinib) of $2.
008 billion (-10.
4% YoY)
.
It is worth mentioning that in the first half of Johnson & Johnson's revenue, the revenue of device products reached 13.
869 billion US dollars, a year-on-year increase of 2.
3%
.
869 billion US dollars, a year-on-year increase of 2.
3%
.
Roche
According to Roche's financial report, in 2022H1, Roche's revenue was 32.
295 billion Swiss francs or about 339.
39 US dollars (according to the exchange rate of 1.
05 on June 30), a year-on-year increase of about 5.
2%
.
Among them, the pharmaceutical business revenue was about 23.
464 billion US dollars, a year-on-year increase of 3%
.
295 billion Swiss francs or about 339.
39 US dollars (according to the exchange rate of 1.
05 on June 30), a year-on-year increase of about 5.
2%
.
Among them, the pharmaceutical business revenue was about 23.
464 billion US dollars, a year-on-year increase of 3%
.
The diagnostic business was approximately US$10.
395 billion, a year-on-year increase of approximately 11.
0%
.
Analysis of its main line products, Ocrevus (ocrelizumab) revenue is about 3.
056 billion US dollars (year-on-year +17%), Perjeta (pertuzumab) is about 2.
164 billion US dollars (year-on-year +5%), Hemlibra (a Mecilizumab) was approximately US$1.
917 billion (+30% year-on-year)
.
It has replaced the original "three-team" AHR as Roche's new "main force"
.
395 billion, a year-on-year increase of approximately 11.
0%
.
Analysis of its main line products, Ocrevus (ocrelizumab) revenue is about 3.
056 billion US dollars (year-on-year +17%), Perjeta (pertuzumab) is about 2.
164 billion US dollars (year-on-year +5%), Hemlibra (a Mecilizumab) was approximately US$1.
917 billion (+30% year-on-year)
.
It has replaced the original "three-team" AHR as Roche's new "main force"
.
Merck & Co (MSD)
In 2022H1, Merck's revenue is about US$30.
5 billion, a year-on-year increase of 38%, ranking third among the world's top 10 companies in terms of growth rate
.
Its pharmaceutical business reported first-half revenue of $26.
9 billion, up 45% year over year
.
Mainly driven by sales growth of Keytruda, Gardasil/Gardasil 9 and Lagevrio
.
It is worth noting that the sales of its PD-1 inhibitor KEYTRUDA (pembrolizumab) reached US$10.
061 billion, a year-on-year increase of 30%
.
5 billion, a year-on-year increase of 38%, ranking third among the world's top 10 companies in terms of growth rate
.
Its pharmaceutical business reported first-half revenue of $26.
9 billion, up 45% year over year
.
Mainly driven by sales growth of Keytruda, Gardasil/Gardasil 9 and Lagevrio
.
It is worth noting that the sales of its PD-1 inhibitor KEYTRUDA (pembrolizumab) reached US$10.
061 billion, a year-on-year increase of 30%
.
At present, Merck is actively conducting joint research on Keytruda and innovative therapies, expecting to further expand the clinical value of Keytruda.
Its sales in 2021 will reach US$17.
186 billion, and it is regarded as the next super blockbuster drug that is expected to exceed US$20 billion.
Its sales in 2021 will reach US$17.
186 billion, and it is regarded as the next super blockbuster drug that is expected to exceed US$20 billion.
AbbVie
In the first half of 2022, AbbVie’s total revenue was US$28.
121 billion, a year-on-year increase of 5.
7%
.
It is worth noting that its Humira 2022H1 sales are about 10.
1 billion US dollars, a year-on-year increase of 2%, accounting for 35.
91% of AbbVie's total sales in the first half of the year, and it is expected to continue to exceed 20 billion US dollars this year
.
121 billion, a year-on-year increase of 5.
7%
.
It is worth noting that its Humira 2022H1 sales are about 10.
1 billion US dollars, a year-on-year increase of 2%, accounting for 35.
91% of AbbVie's total sales in the first half of the year, and it is expected to continue to exceed 20 billion US dollars this year
.
Its blood tumor business revenue was US$3.
3 billion, down 5.
5% year-on-year; its neuroscience business revenue was US$3.
2 billion, a year-on-year increase of 16.
2%; its beauty business revenue was US$2.
7 billion, a year-on-year increase of 6.
6%; but its ophthalmic product revenue was US$1.
5 billion, a year-on-year increase.
A decrease of 14.
3%; the blood and tumor business revenue was US$3.
3 billion, a year-on-year decrease of 5.
5%
.
3 billion, down 5.
5% year-on-year; its neuroscience business revenue was US$3.
2 billion, a year-on-year increase of 16.
2%; its beauty business revenue was US$2.
7 billion, a year-on-year increase of 6.
6%; but its ophthalmic product revenue was US$1.
5 billion, a year-on-year increase.
A decrease of 14.
3%; the blood and tumor business revenue was US$3.
3 billion, a year-on-year decrease of 5.
5%
.
Novartis
On July 19, Novartis announced its semi-annual performance report for 2022
.
Data shows that Novartis’ total revenue in the first half of the year was US$25.
312 billion, which was basically the same as the previous year (US$25.
367 billion); among them, the net profit was US$3.
914 billion, a year-on-year decrease of 21%
.
.
Data shows that Novartis’ total revenue in the first half of the year was US$25.
312 billion, which was basically the same as the previous year (US$25.
367 billion); among them, the net profit was US$3.
914 billion, a year-on-year decrease of 21%
.
In the first half of 2022, the net sales of Novartis innovative drugs were US$20.
6 billion, Entresto (sacubitril-valsartan), Kesimpta (ofatumumab), Cosentyx (secukinumab), Kisqali (libaba) Products such as Sealy) and Zolgensma contributed strong growth drivers
.
Among them, Cosentyx and Entresto are one of the main growth drivers
.
6 billion, Entresto (sacubitril-valsartan), Kesimpta (ofatumumab), Cosentyx (secukinumab), Kisqali (libaba) Products such as Sealy) and Zolgensma contributed strong growth drivers
.
Among them, Cosentyx and Entresto are one of the main growth drivers
.
Cosentyx was approved for a new indication in Europe in the first half of the year, as a monotherapy or in combination with methotrexate, for pediatric patients aged 6 years and older who have an inadequate response to or intolerance to conventional treatments.
Types of juvenile idiopathic arthritis (JIA)
.
Types of juvenile idiopathic arthritis (JIA)
.
The growth of Entresto, which is the first and only treatment approved for the treatment of patients with guideline-defined heart failure, including heart failure patients with reduced ejection fraction (HFrEF) and ejection Heart failure patients with reduced scores (HFpEF)
.
.
It is worth noting that:
Novartis announced in early April that it would integrate the two business divisions of pharmaceuticals and oncology into one division, and at the same time create two independent business organizations—the U.
S.
Innovative Drugs Division and the International Innovative Drugs Division, for which 8,000 people were laid off
.
In this semi-annual report, it is pointed out that with the restructuring and integration, Novartis expects to save about 1.
5 billion US dollars in sales expenses by 2024
.
The savings will be used to invest in follow-on pipelines and contribute to mid- to long-term profit growth in its Innovative Medicines segment (IM)
.
S.
Innovative Drugs Division and the International Innovative Drugs Division, for which 8,000 people were laid off
.
In this semi-annual report, it is pointed out that with the restructuring and integration, Novartis expects to save about 1.
5 billion US dollars in sales expenses by 2024
.
The savings will be used to invest in follow-on pipelines and contribute to mid- to long-term profit growth in its Innovative Medicines segment (IM)
.
In July, Sandoz, Novartis' generic drug business unit, said to the public that Novartis would decide to divest or sell Sandoz by the end of this year
.
The semi-annual report shows that Novartis' strategic review of Sandoz is in progress, and it is expected to provide an update by the end of 2022 at the latest
.
.
The semi-annual report shows that Novartis' strategic review of Sandoz is in progress, and it is expected to provide an update by the end of 2022 at the latest
.
BMS
On July 27, BMS announced its semi-annual performance report for 2022
.
According to the data, the total revenue of BMS in the first half of 2022 is US$23.
535 billion
.
.
According to the data, the total revenue of BMS in the first half of 2022 is US$23.
535 billion
.
BMS divides the listed products into three levels according to the life cycle, namely mature products, newly launched products and products with expired patent period
.
.
Mature products: Eliquis (apixaban), Opdivo (nivolumab) are still maintaining high single-digit and double-digit growth
.
Among them, Eliquis continued to carry the banner of performance, with sales of US$6.
446 billion, a year-on-year increase of 14%
.
Opdivo's revenue was $3.
986 billion, up 10% year-over-year
.
.
Among them, Eliquis continued to carry the banner of performance, with sales of US$6.
446 billion, a year-on-year increase of 14%
.
Opdivo's revenue was $3.
986 billion, up 10% year-over-year
.
Newly launched: Abecma (idecabtagene viccleucel; ide-cel) had sales of $156 million
.
Sales of Reblozyl (Rotesip) were $328 million, an increase of 37% year-over-year
.
.
Sales of Reblozyl (Rotesip) were $328 million, an increase of 37% year-over-year
.
Over-patented products: Revlimid (lenalidomide) faced fierce competition from generic drugs, with sales of US$5.
298 billion, down 14% year-on-year, but still ranked among the top three in BMS sales
.
298 billion, down 14% year-on-year, but still ranked among the top three in BMS sales
.
In addition, the first half of 2022 can be said to be a bumper year for CAR-T product indications
.
BMS' CAR-T product, Abecma, had revenue of $156 million
.
Compared with Abecma's revenue of $0.
24 in the same period in 2021, the growth rate is rapid
.
Although the product with the highest growth rate is Breyanzi (+550%), the potential of Abecma, which has just been launched, is worth looking forward to
.
.
BMS' CAR-T product, Abecma, had revenue of $156 million
.
Compared with Abecma's revenue of $0.
24 in the same period in 2021, the growth rate is rapid
.
Although the product with the highest growth rate is Breyanzi (+550%), the potential of Abecma, which has just been launched, is worth looking forward to
.
AstraZeneca
On July 29, AstraZeneca announced its financial results for the first half of 2022
.
The financial report shows that in the first half of the year, revenue was 22.
161 billion US dollars, an increase of 48% year-on-year; R&D investment was 4.
679 billion US dollars, a year-on-year increase of 35%, accounting for 21% of revenue
.
.
The financial report shows that in the first half of the year, revenue was 22.
161 billion US dollars, an increase of 48% year-on-year; R&D investment was 4.
679 billion US dollars, a year-on-year increase of 35%, accounting for 21% of revenue
.
The oncology business was US$7.
5 billion, a year-on-year increase of 22%, with the fastest revenue growth; among them, the third-generation EGFR-TKI osimertinib contributed the most, with revenue of US$2.
704 billion, a year-on-year increase of 14%
.
Cardiovascular, renal and metabolic diseases (CVRM) business was US$4.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
5 billion
.
5 billion, a year-on-year increase of 22%, with the fastest revenue growth; among them, the third-generation EGFR-TKI osimertinib contributed the most, with revenue of US$2.
704 billion, a year-on-year increase of 14%
.
Cardiovascular, renal and metabolic diseases (CVRM) business was US$4.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
5 billion
.
It is also striking that AstraZeneca has undergone frequent changes in the past six months, with structural adjustments and acquisitions:
In January, AstraZeneca announced the official establishment of the Omni-Channel Business Unit, and appointed Liu Qian, Vice President of AstraZeneca China, as the head of the Omni-Channel Business Unit, and comprehensively led the AstraZeneca China and County Chronic Disease Business Unit, Retail Business Unit, and Community Business Unit , Flying Eagle Business Department and Dongwu County Market
.
.
In June, AstraZeneca China's original innovation market positions in various business divisions will be officially transferred to the CCIC innovation disease management team of the Digital and Business Innovation Department, and a business innovation team based on therapeutic areas and Quanliangdao will be formed
.
.
In July, AstraZeneca completed the acquisition of rare disease giant Alexion Pharmaceuticals
.
.
Sanofi
On July 28, Sanofi released its 2022 semi-annual performance report
.
Data show that in the first half of the year, total revenue was 19.
79 billion euros (20.
148 billion U.
S.
dollars), a year-on-year increase of 14.
2%; net profit was 3.
184 billion euros (3.
242 billion U.
S.
dollars), a year-on-year increase of 15.
2%
.
.
Data show that in the first half of the year, total revenue was 19.
79 billion euros (20.
148 billion U.
S.
dollars), a year-on-year increase of 14.
2%; net profit was 3.
184 billion euros (3.
242 billion U.
S.
dollars), a year-on-year increase of 15.
2%
.
Sanofi's business sources are composed of four sectors: specialty medicines, vaccines, general medicines and consumer healthcare
.
.
Specifically, Sanofi's vaccine business revenue was 2.
198 billion euros, a year-on-year increase of 7.
8%; consumer health care business revenue was 2.
593 billion euros, a year-on-year increase of 13.
1%
.
The pharmaceutical business (special drugs + general drugs) mainly focuses on immune inflammation, neurology, rare diseases, tumors, diabetes and other fields, with revenue of 14.
999 billion euros in the first half of the year, a year-on-year increase of 7.
7%
.
Dupixent (duprilumab) is Sanofi's ace product, with revenue of 3.
577 billion euros in the first half of 2022, a year-on-year increase of 44.
4%
.
198 billion euros, a year-on-year increase of 7.
8%; consumer health care business revenue was 2.
593 billion euros, a year-on-year increase of 13.
1%
.
The pharmaceutical business (special drugs + general drugs) mainly focuses on immune inflammation, neurology, rare diseases, tumors, diabetes and other fields, with revenue of 14.
999 billion euros in the first half of the year, a year-on-year increase of 7.
7%
.
Dupixent (duprilumab) is Sanofi's ace product, with revenue of 3.
577 billion euros in the first half of 2022, a year-on-year increase of 44.
4%
.
Sanofi also made major structural adjustments:
In March, in order to implement the "Play-to-Win" strategy, Sanofi will adjust the existing team structure and resources of Sanofi Vaccines China, combining key customer teams, hospital customer teams, business innovation teams, market operations and Optimize the team and integrate with the business promotion team
.
At the same time, Zhou You, the former chief marketing officer of Sanofi, decided to seek external development of the company
.
.
At the same time, Zhou You, the former chief marketing officer of Sanofi, decided to seek external development of the company
.
In June, Sanofi announced that from August 1, Schwann will serve as the president of Sanofi Greater China and the head of general medicine
.
Dr.
He Enting, former president of Sanofi Greater China, will be the global head of Sanofi's digital business unit from August 1
.
After taking up his new role, He Enting will work at Sanofi's Paris headquarters and be responsible for defining and implementing the digital solution portfolio of Sanofi's global business unit of pharmaceuticals, specialty medicines and vaccines
.
.
Dr.
He Enting, former president of Sanofi Greater China, will be the global head of Sanofi's digital business unit from August 1
.
After taking up his new role, He Enting will work at Sanofi's Paris headquarters and be responsible for defining and implementing the digital solution portfolio of Sanofi's global business unit of pharmaceuticals, specialty medicines and vaccines
.
GSK
On July 27, GlaxoSmithKline (GSK) announced its financial results for the first half of 2022
.
According to the financial report, total revenue in the first half of the year was 14.
119 billion pounds ($17.
157 billion), a year-on-year increase of 28%
.
.
According to the financial report, total revenue in the first half of the year was 14.
119 billion pounds ($17.
157 billion), a year-on-year increase of 28%
.
GSK's business sources are divided into three major modules: specialty drugs, vaccines and general drugs
.
Among them, the revenue of specialty drugs was 5.
839 billion pounds, an increase of 69% year-on-year, HIV drug revenue was 2.
585 billion pounds; vaccine revenue was 3.
384 billion pounds, an increase of 21% year-on-year, and the sales of shingles vaccine Shinggrix more than doubled to 731 million pounds; Generic medicine revenue was £4.
896 billion, up 3% year-on-year
.
.
Among them, the revenue of specialty drugs was 5.
839 billion pounds, an increase of 69% year-on-year, HIV drug revenue was 2.
585 billion pounds; vaccine revenue was 3.
384 billion pounds, an increase of 21% year-on-year, and the sales of shingles vaccine Shinggrix more than doubled to 731 million pounds; Generic medicine revenue was £4.
896 billion, up 3% year-on-year
.
The earnings season is approaching, and major MNCs (multinational pharmaceutical companies) have successively released their semi-annual reports
.
.
Pfizer, which has the first growth rate in 2021 (up 95% year-on-year), remains firmly in MNCTOP1 with the growth of new crown vaccines and new crown drugs, and ushered in a double-digit growth of 60% in the first half of the year
.
.
According to the total revenue of pharmaceutical companies, the top 10 global revenue are: Pfizer ($53.
402 billion), Johnson & Johnson ($47.
446 billion), Roche ($33.
761 billion), Merck ($30.
494 billion), AbbVie ($28.
121 billion) $), Novartis ($25.
312 billion), Bristol-Myers Squibb ($23.
535 billion), AstraZeneca ($21.
161 billion), Sanofi ($20.
122 billion), GlaxoSmithKline ($17.
194 billion)
.
402 billion), Johnson & Johnson ($47.
446 billion), Roche ($33.
761 billion), Merck ($30.
494 billion), AbbVie ($28.
121 billion) $), Novartis ($25.
312 billion), Bristol-Myers Squibb ($23.
535 billion), AstraZeneca ($21.
161 billion), Sanofi ($20.
122 billion), GlaxoSmithKline ($17.
194 billion)
.
According to the MNC semi-annual report, the top 10 best-selling drugs in 2022H1 are as follows:
Now, let's take a closer look at the performance of each company
.
.
Top 10 companies
TOP10 Enterprise Enterprise Enterprise Situation Pfizer
Pfizer According to Pfizer’s financial report, 2022H1 revenue is US$53.
402 billion, an increase of 60% from US$33.
415 billion in the first half of 2021
.
And its net profit growth has reached 70%
.
Among them, the vaccine Comirnaty is worth 22.
1 billion US dollars, and the new crown specific drug Paxlovid is 9.
6 billion US dollars, or about 31.
7 billion US dollars, which are the main income of the company
.
The revenue of its new crown products alone directly surpasses the 32 billion US dollars of Roche, a TOP10MNC
.
402 billion, an increase of 60% from US$33.
415 billion in the first half of 2021
.
And its net profit growth has reached 70%
.
Among them, the vaccine Comirnaty is worth 22.
1 billion US dollars, and the new crown specific drug Paxlovid is 9.
6 billion US dollars, or about 31.
7 billion US dollars, which are the main income of the company
.
The revenue of its new crown products alone directly surpasses the 32 billion US dollars of Roche, a TOP10MNC
.
Excluding its new crown field, Pfizer's other main lines of business, breast cancer drug Ibrance (Aiboxin) 25.
57 billion US dollars, prostate cancer drug Xtandi (Astery) 5.
58 billion US dollars in the tumor field have a certain amount of decline year-on-year
.
57 billion US dollars, prostate cancer drug Xtandi (Astery) 5.
58 billion US dollars in the tumor field have a certain amount of decline year-on-year
.
Relatively speaking, its Eliquis (apixaban) ($3.
537 billion, +13%), Prevnar family (Streptococcus pneumoniae vaccine) $2.
994 billion (+19% year-on-year), rare heart disease drug Vyndaqel/Vyndamax (Vivan Heart) $1.
164 billion (+22% year-on-year), Inlyta (axitinib) ($508 million, +4% year-on-year)
.
heart heart537 billion, +13%), Prevnar family (Streptococcus pneumoniae vaccine) $2.
994 billion (+19% year-on-year), rare heart disease drug Vyndaqel/Vyndamax (Vivan Heart) $1.
164 billion (+22% year-on-year), Inlyta (axitinib) ($508 million, +4% year-on-year)
.
Johnson & Johnson
Johnson & Johnson Johnson & Johnson's 2022H1 financial report shows that its revenue has also reached $47.
446 billion, a year-on-year increase of 4.
0%
.
But the pharmaceutical business accounted for $26.
186 billion of that, up 6.
5% year-on-year
.
Analysis of its main top three products: STELARA (ustekinumab), one of the three giants in the field of self-immunity, was $4.
887 billion (+10.
5% year-on-year), and DARZALEX (daratumumab) was $3.
842 billion ( +37.
0% YoY) and its Imbruvica (ibrutinib) of $2.
008 billion (-10.
4% YoY)
.
446 billion, a year-on-year increase of 4.
0%
.
But the pharmaceutical business accounted for $26.
186 billion of that, up 6.
5% year-on-year
.
Analysis of its main top three products: STELARA (ustekinumab), one of the three giants in the field of self-immunity, was $4.
887 billion (+10.
5% year-on-year), and DARZALEX (daratumumab) was $3.
842 billion ( +37.
0% YoY) and its Imbruvica (ibrutinib) of $2.
008 billion (-10.
4% YoY)
.
It is worth mentioning that in the first half of Johnson & Johnson's revenue, the revenue of device products reached 13.
869 billion US dollars, a year-on-year increase of 2.
3%
.
869 billion US dollars, a year-on-year increase of 2.
3%
.
Roche
Roche According to Roche's financial report, in 2022H1, Roche's revenue was 32.
295 billion Swiss francs or about 339.
39 US dollars (according to the exchange rate of 1.
05 on June 30), a year-on-year increase of about 5.
2%
.
Among them, the pharmaceutical business revenue was about 23.
464 billion US dollars, a year-on-year increase of 3%
.
295 billion Swiss francs or about 339.
39 US dollars (according to the exchange rate of 1.
05 on June 30), a year-on-year increase of about 5.
2%
.
Among them, the pharmaceutical business revenue was about 23.
464 billion US dollars, a year-on-year increase of 3%
.
The diagnostic business was approximately US$10.
395 billion, a year-on-year increase of approximately 11.
0%
.
Analysis of its main line products, Ocrevus (ocrelizumab) revenue is about 3.
056 billion US dollars (year-on-year +17%), Perjeta (pertuzumab) is about 2.
164 billion US dollars (year-on-year +5%), Hemlibra (a Mecilizumab) was approximately US$1.
917 billion (+30% year-on-year)
.
It has replaced the original "three-team" AHR as Roche's new "main force"
.
395 billion, a year-on-year increase of approximately 11.
0%
.
Analysis of its main line products, Ocrevus (ocrelizumab) revenue is about 3.
056 billion US dollars (year-on-year +17%), Perjeta (pertuzumab) is about 2.
164 billion US dollars (year-on-year +5%), Hemlibra (a Mecilizumab) was approximately US$1.
917 billion (+30% year-on-year)
.
It has replaced the original "three-team" AHR as Roche's new "main force"
.
Merck & Co (MSD)
Merck & Co (MSD) In 2022H1, Merck's revenue is about US$30.
5 billion, a year-on-year increase of 38%, ranking third among the world's top 10 companies in terms of growth rate
.
Its pharmaceutical business reported first-half revenue of $26.
9 billion, up 45% year over year
.
Mainly driven by sales growth of Keytruda, Gardasil/Gardasil 9 and Lagevrio
.
It is worth noting that the sales of its PD-1 inhibitor KEYTRUDA (pembrolizumab) reached US$10.
061 billion, a year-on-year increase of 30%
.
5 billion, a year-on-year increase of 38%, ranking third among the world's top 10 companies in terms of growth rate
.
Its pharmaceutical business reported first-half revenue of $26.
9 billion, up 45% year over year
.
Mainly driven by sales growth of Keytruda, Gardasil/Gardasil 9 and Lagevrio
.
It is worth noting that the sales of its PD-1 inhibitor KEYTRUDA (pembrolizumab) reached US$10.
061 billion, a year-on-year increase of 30%
.
At present, Merck is actively conducting joint research on Keytruda and innovative therapies, expecting to further expand the clinical value of Keytruda.
Its sales in 2021 will reach US$17.
186 billion, and it is regarded as the next super blockbuster drug that is expected to exceed US$20 billion.
Its sales in 2021 will reach US$17.
186 billion, and it is regarded as the next super blockbuster drug that is expected to exceed US$20 billion.
AbbVie
AbbVie In the first half of 2022, AbbVie’s total revenue was US$28.
121 billion, a year-on-year increase of 5.
7%
.
It is worth noting that its Humira 2022H1 sales are about 10.
1 billion US dollars, a year-on-year increase of 2%, accounting for 35.
91% of AbbVie's total sales in the first half of the year, and it is expected to continue to exceed 20 billion US dollars this year
.
121 billion, a year-on-year increase of 5.
7%
.
It is worth noting that its Humira 2022H1 sales are about 10.
1 billion US dollars, a year-on-year increase of 2%, accounting for 35.
91% of AbbVie's total sales in the first half of the year, and it is expected to continue to exceed 20 billion US dollars this year
.
Its blood tumor business revenue was US$3.
3 billion, down 5.
5% year-on-year; its neuroscience business revenue was US$3.
2 billion, a year-on-year increase of 16.
2%; its beauty business revenue was US$2.
7 billion, a year-on-year increase of 6.
6%; but its ophthalmic product revenue was US$1.
5 billion, a year-on-year increase.
A decrease of 14.
3%; the blood and tumor business revenue was US$3.
3 billion, a year-on-year decrease of 5.
5%
.
3 billion, down 5.
5% year-on-year; its neuroscience business revenue was US$3.
2 billion, a year-on-year increase of 16.
2%; its beauty business revenue was US$2.
7 billion, a year-on-year increase of 6.
6%; but its ophthalmic product revenue was US$1.
5 billion, a year-on-year increase.
A decrease of 14.
3%; the blood and tumor business revenue was US$3.
3 billion, a year-on-year decrease of 5.
5%
.
Novartis
Novartis On July 19, Novartis announced its semi-annual performance report for 2022
.
Data shows that Novartis’ total revenue in the first half of the year was US$25.
312 billion, which was basically the same as the previous year (US$25.
367 billion); among them, the net profit was US$3.
914 billion, a year-on-year decrease of 21%
.
.
Data shows that Novartis’ total revenue in the first half of the year was US$25.
312 billion, which was basically the same as the previous year (US$25.
367 billion); among them, the net profit was US$3.
914 billion, a year-on-year decrease of 21%
.
In the first half of 2022, the net sales of Novartis innovative drugs were US$20.
6 billion, Entresto (sacubitril-valsartan), Kesimpta (ofatumumab), Cosentyx (secukinumab), Kisqali (libaba) Products such as Sealy) and Zolgensma contributed strong growth drivers
.
Among them, Cosentyx and Entresto are one of the main growth drivers
.
6 billion, Entresto (sacubitril-valsartan), Kesimpta (ofatumumab), Cosentyx (secukinumab), Kisqali (libaba) Products such as Sealy) and Zolgensma contributed strong growth drivers
.
Among them, Cosentyx and Entresto are one of the main growth drivers
.
Cosentyx was approved for a new indication in Europe in the first half of the year, as a monotherapy or in combination with methotrexate, for pediatric patients aged 6 years and older who have an inadequate response to or intolerance to conventional treatments.
Types of juvenile idiopathic arthritis (JIA)
.
Types of juvenile idiopathic arthritis (JIA)
.
The growth of Entresto, which is the first and only treatment approved for the treatment of patients with guideline-defined heart failure, including heart failure patients with reduced ejection fraction (HFrEF) and ejection Heart failure patients with reduced scores (HFpEF)
.
.
It is worth noting that:
It is worth noting that: Novartis announced in early April that it would integrate the two business divisions of pharmaceuticals and oncology into one division, and at the same time create two independent business organizations—the U.
S.
Innovative Drugs Division and the International Innovative Drugs Division, for which 8,000 people were laid off
.
In this semi-annual report, it is pointed out that with the restructuring and integration, Novartis expects to save about 1.
5 billion US dollars in sales expenses by 2024
.
The savings will be used to invest in follow-on pipelines and contribute to mid- to long-term profit growth in its Innovative Medicines segment (IM)
.
S.
Innovative Drugs Division and the International Innovative Drugs Division, for which 8,000 people were laid off
.
In this semi-annual report, it is pointed out that with the restructuring and integration, Novartis expects to save about 1.
5 billion US dollars in sales expenses by 2024
.
The savings will be used to invest in follow-on pipelines and contribute to mid- to long-term profit growth in its Innovative Medicines segment (IM)
.
In July, Sandoz, Novartis' generic drug business unit, said to the public that Novartis would decide to divest or sell Sandoz by the end of this year
.
The semi-annual report shows that Novartis' strategic review of Sandoz is in progress, and it is expected to provide an update by the end of 2022 at the latest
.
.
The semi-annual report shows that Novartis' strategic review of Sandoz is in progress, and it is expected to provide an update by the end of 2022 at the latest
.
BMS
BMS On July 27, BMS announced its semi-annual performance report for 2022
.
According to the data, the total revenue of BMS in the first half of 2022 is US$23.
535 billion
.
.
According to the data, the total revenue of BMS in the first half of 2022 is US$23.
535 billion
.
BMS divides the listed products into three levels according to the life cycle, namely mature products, newly launched products and products with expired patent period
.
.
Mature products: Eliquis (apixaban), Opdivo (nivolumab) are still maintaining high single-digit and double-digit growth
.
Among them, Eliquis continued to carry the banner of performance, with sales of US$6.
446 billion, a year-on-year increase of 14%
.
Opdivo's revenue was $3.
986 billion, up 10% year-over-year
.
.
Among them, Eliquis continued to carry the banner of performance, with sales of US$6.
446 billion, a year-on-year increase of 14%
.
Opdivo's revenue was $3.
986 billion, up 10% year-over-year
.
Newly launched: Abecma (idecabtagene viccleucel; ide-cel) had sales of $156 million
.
Sales of Reblozyl (Rotesip) were $328 million, an increase of 37% year-over-year
.
.
Sales of Reblozyl (Rotesip) were $328 million, an increase of 37% year-over-year
.
Over-patented products: Revlimid (lenalidomide) faced fierce competition from generic drugs, with sales of US$5.
298 billion, down 14% year-on-year, but still ranked among the top three in BMS sales
.
298 billion, down 14% year-on-year, but still ranked among the top three in BMS sales
.
In addition, the first half of 2022 can be said to be a bumper year for CAR-T product indications
.
BMS' CAR-T product, Abecma, had revenue of $156 million
.
Compared with Abecma's revenue of $0.
24 in the same period in 2021, the growth rate is rapid
.
Although the product with the highest growth rate is Breyanzi (+550%), the potential of Abecma, which has just been launched, is worth looking forward to
.
.
BMS' CAR-T product, Abecma, had revenue of $156 million
.
Compared with Abecma's revenue of $0.
24 in the same period in 2021, the growth rate is rapid
.
Although the product with the highest growth rate is Breyanzi (+550%), the potential of Abecma, which has just been launched, is worth looking forward to
.
AstraZeneca
AstraZeneca On July 29, AstraZeneca announced its financial results for the first half of 2022
.
The financial report shows that in the first half of the year, revenue was 22.
161 billion US dollars, an increase of 48% year-on-year; R&D investment was 4.
679 billion US dollars, a year-on-year increase of 35%, accounting for 21% of revenue
.
.
The financial report shows that in the first half of the year, revenue was 22.
161 billion US dollars, an increase of 48% year-on-year; R&D investment was 4.
679 billion US dollars, a year-on-year increase of 35%, accounting for 21% of revenue
.
The oncology business was US$7.
5 billion, a year-on-year increase of 22%, with the fastest revenue growth; among them, the third-generation EGFR-TKI osimertinib contributed the most, with revenue of US$2.
704 billion, a year-on-year increase of 14%
.
Cardiovascular, renal and metabolic diseases (CVRM) business was US$4.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
5 billion
.
disease disease5 billion, a year-on-year increase of 22%, with the fastest revenue growth; among them, the third-generation EGFR-TKI osimertinib contributed the most, with revenue of US$2.
704 billion, a year-on-year increase of 14%
.
Cardiovascular, renal and metabolic diseases (CVRM) business was US$4.
6 billion, an increase of 19% year-on-year; the rare disease business grew rapidly, with total revenue reaching US$3.
5 billion
.
It is also striking that AstraZeneca has undergone frequent changes in the past six months, with structural adjustments and acquisitions:
In January, AstraZeneca announced the official establishment of the Omni-Channel Business Unit, and appointed Liu Qian, Vice President of AstraZeneca China, as the head of the Omni-Channel Business Unit, and comprehensively led the AstraZeneca China and County Chronic Disease Business Unit, Retail Business Unit, and Community Business Unit , Flying Eagle Business Department and Dongwu County Market
.
.
In June, AstraZeneca China's original innovation market positions in various business divisions will be officially transferred to the CCIC innovation disease management team of the Digital and Business Innovation Department, and a business innovation team based on therapeutic areas and Quanliangdao will be formed
.
.
In July, AstraZeneca completed the acquisition of rare disease giant Alexion Pharmaceuticals
.
.
Sanofi
Sanofi On July 28, Sanofi released its 2022 semi-annual performance report
.
Data show that in the first half of the year, total revenue was 19.
79 billion euros (20.
148 billion U.
S.
dollars), a year-on-year increase of 14.
2%; net profit was 3.
184 billion euros (3.
242 billion U.
S.
dollars), a year-on-year increase of 15.
2%
.
.
Data show that in the first half of the year, total revenue was 19.
79 billion euros (20.
148 billion U.
S.
dollars), a year-on-year increase of 14.
2%; net profit was 3.
184 billion euros (3.
242 billion U.
S.
dollars), a year-on-year increase of 15.
2%
.
Sanofi's business sources are composed of four sectors: specialty medicines, vaccines, general medicines and consumer healthcare
.
health care.
Specifically, Sanofi's vaccine business revenue was 2.
198 billion euros, a year-on-year increase of 7.
8%; consumer health care business revenue was 2.
593 billion euros, a year-on-year increase of 13.
1%
.
The pharmaceutical business (special drugs + general drugs) mainly focuses on immune inflammation, neurology, rare diseases, tumors, diabetes and other fields, with revenue of 14.
999 billion euros in the first half of the year, a year-on-year increase of 7.
7%
.
Dupixent (duprilumab) is Sanofi's ace product, with revenue of 3.
577 billion euros in the first half of 2022, a year-on-year increase of 44.
4%
.
198 billion euros, a year-on-year increase of 7.
8%; consumer health care business revenue was 2.
593 billion euros, a year-on-year increase of 13.
1%
.
The pharmaceutical business (special drugs + general drugs) mainly focuses on immune inflammation, neurology, rare diseases, tumors, diabetes and other fields, with revenue of 14.
999 billion euros in the first half of the year, a year-on-year increase of 7.
7%
.
Dupixent (duprilumab) is Sanofi's ace product, with revenue of 3.
577 billion euros in the first half of 2022, a year-on-year increase of 44.
4%
.
Sanofi also made major structural adjustments:
Sanofi also made major structural adjustments: In March, in order to implement the "Play-to-Win" strategy, Sanofi will adjust the existing team structure and resources of Sanofi Vaccines China, combining key customer teams, hospital customer teams, business innovation teams, market operations and Optimize the team and integrate with the business promotion team
.
At the same time, Zhou You, the former chief marketing officer of Sanofi, decided to seek external development of the company
.
hospital hospital.
At the same time, Zhou You, the former chief marketing officer of Sanofi, decided to seek external development of the company
.
In June, Sanofi announced that from August 1, Schwann will serve as the president of Sanofi Greater China and the head of general medicine
.
Dr.
He Enting, former president of Sanofi Greater China, will be the global head of Sanofi's digital business unit from August 1
.
After taking up his new role, He Enting will work at Sanofi's Paris headquarters and be responsible for defining and implementing the digital solution portfolio of Sanofi's global business unit of pharmaceuticals, specialty medicines and vaccines
.
.
Dr.
He Enting, former president of Sanofi Greater China, will be the global head of Sanofi's digital business unit from August 1
.
After taking up his new role, He Enting will work at Sanofi's Paris headquarters and be responsible for defining and implementing the digital solution portfolio of Sanofi's global business unit of pharmaceuticals, specialty medicines and vaccines
.
GSK
GSK On July 27, GlaxoSmithKline (GSK) announced its financial results for the first half of 2022
.
According to the financial report, total revenue in the first half of the year was 14.
119 billion pounds ($17.
157 billion), a year-on-year increase of 28%
.
.
According to the financial report, total revenue in the first half of the year was 14.
119 billion pounds ($17.
157 billion), a year-on-year increase of 28%
.
GSK's business sources are divided into three major modules: specialty drugs, vaccines and general drugs
.
Among them, the revenue of specialty drugs was 5.
839 billion pounds, an increase of 69% year-on-year, HIV drug revenue was 2.
585 billion pounds; vaccine revenue was 3.
384 billion pounds, an increase of 21% year-on-year, and the sales of shingles vaccine Shinggrix more than doubled to 731 million pounds; Generic medicine revenue was £4.
896 billion, up 3% year-on-year
.
.
Among them, the revenue of specialty drugs was 5.
839 billion pounds, an increase of 69% year-on-year, HIV drug revenue was 2.
585 billion pounds; vaccine revenue was 3.
384 billion pounds, an increase of 21% year-on-year, and the sales of shingles vaccine Shinggrix more than doubled to 731 million pounds; Generic medicine revenue was £4.
896 billion, up 3% year-on-year
.
